Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2012

View Archived Issues

Ciclopiroxolamine evaluated in patients with hematological malignancies

Mouse model mimics characteristics of Tourette syndrome observed in patients

Soligenix acquires innate defense regulator

Neurocrine begins second phase IIb study of NBI-98854

Primary endpoint not met in phase III trial of L-BLP25 in NSCLC

iPSC-derived neurons as a model for AD treatment screening / News in Context

Japanese and U.S. group patents novel TRPV1 channel antagonists

Principia Biopharma discloses new protein kinase inhibitors

Gentium provides update on MAA for defibrotide

Arrowhead and Shire enter agreement to develop peptide-targeted therapeutics

MAA filed in Japan for additional pediatric indication of topiramate

Concert Pharmaceuticals synthesizes new deuterated CFTR activators

NewGen Therapeutics patents new agents for cancer

Novel antitumor metal complexes designed by Unitech

University of Toyama prepares new beta-carboline derivatives for cancer

IPI-145 well tolerated and active in patients with hematological malignancies

Researchers present clinical trial results on NOX-H94 for the treatment of ACD

Intercell obtains positive CHMP opinion for pediatric use of its JE vaccine

Amgen licenses rights to TAP technology for third cancer target

Allon Therapeutics' phase II/III trial of davunetide fails to show efficacy

UMN Pharma signs license agreement with Ildong Pharmaceutical for influenza vaccines

GlycoVaxyn and GSK enter collaboration to develop new bacterial vaccines

Idera Pharmaceuticals reports results from phase IIa IMO-3100 trial

Intercept Pharmaceuticals completes enrollment in phase III POISE Trial

MethylGene's phase II trial of MGCD-290 completes enrollment

Prana Biotechnology completes recruitment in Reach2HD study

BAY-80-6946 activity in non-Hodgkin's lymphoma leads to phase II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...